Sphingosine kinase and sphingosine 1-phosphate in cardioprotection

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 3, 2009, Pages 189-197

  Karliner, Joel S ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardioprotection; Cell signaling; Dimethylsphingosine; High density lipoprotein; S1P receptors; Sphingosine 1 phosphate; Sphingosine kinase

Indexed keywords

2 AMINO 2 (3 OCTYLPHENYLCARBAMOYL)ETHYL PHOSPHATE; 5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; FINGOLIMOD; GANGLIOSIDE GM1; HIGH DENSITY LIPOPROTEIN; ISOFLURANE; N,N DIMETHYLSPHINGOSINE; PROTEIN KINASE C EPSILON; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2; CARDIOTONIC AGENT; DRUG DERIVATIVE; LYSOPHOSPHOLIPID; PHOSPHOTRANSFERASE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

CELL SURVIVAL; DRUG ACTIVITY; ENZYME ACTIVITY; HEART CELL CULTURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; ANIMAL; CELL CULTURE; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; FIBROBLAST; HEART MUSCLE CELL; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOTONIC AGENTS; CELL SURVIVAL; CELLS, CULTURED; FIBROBLASTS; HUMANS; LYSOPHOSPHOLIPIDS; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 67649240622     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181926706     Document Type: Review

References (124)

1. Cuvillier O, Pirianov G, Keluser B, et al. Suppression of ceramidemediated programmed cell death by sphingosine-1-phosphate. Nature. 1996;381:800-803. (Pubitemid 26243122)
2. Allende ML, Proia RL. Sphingosine-1-phosphate receptors and the development of the vascular system. Biochim Biophys Acta. 2002;1582: 222-227.
3. Wendler CC, Rivkees SA. Sphingosine-1-phosphate inhibits cell migration and endothelial to mesenchymal cell transformation during cardiac development. Dev Biol. 2006;291:264-277.
4. Yatomi Y. Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases. Curr Pharm Des. 2006;12:575-587.
5. Peters SLM, Alewijnse AE. Sphingosine-1-phosphate signaling in the cardiovascular system. Curr Opin Pharmacol. 2007;7:186-192.
6. Alemany R, van Koppen CJ, Dannebeg K, et al. Regulation and functional roles of sphingosine kinases. Naunyn-Schmiedeberg Arch Pharmacol. 2007;374:413-428. (Pubitemid 46215289)
7. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9:139-150.
8. Alewijnse AE, Peters SLM. Sphingolipid signalling in the cardiovascular system: good, bad or both? Eur J Pharmacol. 2008;585:292-302.
9. Imamura T, Ohgane J, Ito S, et al. CpG island of rat sphingosine kinase-1 gene: tissue-dependent DNA methylation status and multiple alternative first exons. Genomics. 2001;76:117-125. (Pubitemid 32744631)
10. Okada T, Ding G, Sonoda H, et al. Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis. J Biol Chem. 2005;280:36318-36325. (Pubitemid 41633905)
11. Liu H, Sugiura M, Nava VE, et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem. 2000;275:19513-19520. (Pubitemid 30441543)
12. Mizugishi K, Yamashita T, Olivera A, et al. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol. 2005;25: 11113-11121. (Pubitemid 41747151)
13. Allende ML, Sasaaki T, Kawai H, et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem. 2004;279: 52487-52492. (Pubitemid 39656625)
14. Michaud J, Kohno M, Proia RL, et al. Normal acute and chronic inflammatory responses in sphingosine kianse 1 knockout mice. FEBS Lett. 2006;580:4607-4612. (Pubitemid 44189376)
15. Cavallini L, Venerando R, Miotto G, et al. Ganglioside GM1 protection from apoptosis of rat heart fibroblasts. Arch Biochem Biophys. 1999;370: 156-162. (Pubitemid 29491420)
16. Pitson SM, Moretti PA, Zebol JR, et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 2003;22: 5491-5500. (Pubitemid 37279958)
17. Xia P, Wang L, Moretti PA, et al. Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor alpha signaling. J Biol Chem. 2002;277:7996-8003. (Pubitemid 34968251)
18. Fujita T, Okada T, Hayshi S, et al. Delta-catenin/NRRAP (neural plakophilin-related armadillo repeat protein) interacts with and activates sphingosine kinase 1. Biochem J. 2004;382:717-723. (Pubitemid 39243938)
19. Maceyka M, Payne SG, Milstien S, et al. Aminocyclase 1 is a sphingosine kinase 1-interacting protein. FEBS Lett. 2004;568:30-34. (Pubitemid 38757950)
20. Leclercq TM, Moretti PA, Vadas MA, et al. Eukaryotic elongation factor 1 interacts with sphingosine kinase and directly enhances its catalytic activity. J Biol Chem. 2008;283:9606-9614.
21. Lacana E, Maceyka M, Milstien S, et al. Cloning and characterization of a protein kinase A anchoring protein (AKAP)-related protein that interacts with and regulates sphingosine kinase 1 activity. J Biol Chem. 2002;277:32947-32953. (Pubitemid 34984808)
22. Fukuda Y, Aoyama Y, Wada A, et al. Identification of PECAM-1 association with sphingosine kinase 1 and its regulation by agonistinduced phosphorylation. Biochim Biophys Acta. 2004;1636:12-21. (Pubitemid 38231000)
23. Sun J, Yan G, Ren A, et al. FHL2/SLIM3 decreases cardiomyocyte survival by inhibitory interaction with sphingosine kinase-1. Circ Res. 2006;99:468-476. (Pubitemid 44337818)
24. Hayashi S, Okada T, Igararshi N, et al. Identification and characterization of RPK118, a novel sphingosine kinase-1-binding protein. J Biol Chem. 2002;277:33319-33324. (Pubitemid 34984853)
25. Melendez AJ, Khaw AK. Dichotomy of Ca2+ signals triggered by different phospholipid pathways in antigen stimulation of human mast cells. J Biol Chem. 2002;277:17255-17262.
26. Meyer zu Heringdorf D. Lysophospholipid receptor-dependent and -independent calcium signaling. J Cell Biochem. 2004;92:937-948.
27. Venkataraman K, Thangada S, Michaud J, et al. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem J. 2006;397:461-471. (Pubitemid 44187504)
28. Mitra P, Oskeritian CA, Payne SG, et al. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci U S A. 2006;103:16394-16399. (Pubitemid 44715207)
29. Pchejetski D, Kunduzova O, Dayhon A, et al. Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res. 2007;100:41-49. (Pubitemid 46066772)
30. Anelli V, Gault CR, Cheng AB, et al. Sphingosine kinase 1 is upregulated during hypoxia in U87MG glioma cells. Role of hypoxiainducible factors 1 and 2. J Biol Chem. 2008;283:3365-3375.
31. Vessey DA, Kelley M, Zhang J, et al. Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart. J Biochem Mol Toxicol. 2007;21: 273-279. (Pubitemid 350006284)
32. Taha TA, Kitatani K, El-Alwani M, et al. Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis. FASEB J. 2006;20: 482-484. (Pubitemid 46671223)
33. Cuvillier O, Levade T. Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/ DIABLO from mitochondria. Blood. 2001;98:2828-2836.
34. Dindo D, Dahm F, Szulc Z, et al. Cationic long-chain ceramide LCL-30 induces cell death by mitochondrial targeting in SW403 cells. Mol Cancer Ther. 2006;5:1520-1529. (Pubitemid 44070489)
35. Gustafsson AB, Gottlieb RA. Recycle or die: the role of autophagy in cardioprotection. J Mol Cell Cardiol. 2008;44:654-661.
36. Lavieu G, Scarlatti F, Sala G, et al. Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation. J Biol Chem. 2006;281:8518-8527. (Pubitemid 43847954)
37. Lavieu G, Scarlatti F, Sala G, et al. Is autophagy the key mechanism by which the sphingolipid rheostat controls the cell fate decision? Autophagy. 2007;3:45-47.
38. Tao R, Zhang J, Vessey DA, et al. Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res. 2007;74:56-63. (Pubitemid 46366955)
39. Gude DR, Alvarez SE, Paugh SW, et al. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and- get-me" signal. FASEB J. 2008;22:2629-2638.
40. Maceyka M, Sankkala H, Hait NC, et al. SphK1 and Sphk2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem. 2005;280:37118-37129. (Pubitemid 41587796)
41. Okada T, Ding G, Sonoda H, et al. Involvement of N-terminal extended form of sphingosine kinase-2 in serum dependent cell proliferation and apoptosis. J Biol Chem. 2005;280:36318-36325. (Pubitemid 41633905)
42. Igarashi N, Okada T, Hayashi S, et al. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem. 2003;278: 46832-46839. (Pubitemid 37452263)
43. Liu H, Toman RE, Goparaju SK, et al. Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J Biol Chem. 2003; 278:40330-40336. (Pubitemid 37248601)
44. Merrill AH Jr, Schmelz EM, Dillehay DL, et al. Sphingolipids-the enigmatic lipid class: biochemistry, physiology and pathophysiology. Toxicol Appl Pharmacol. 1997;142:208-225.
45. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115:84-105. (Pubitemid 46990553)
46. Kappos L, Antel J, Comi G, et al, for the FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124-1140.
47. Maceyka M, Payne SG, Milstien S, et al. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta. 2002; 1585:193-201.
48. Saba JD, Hla T. Point-counterpoint of sphingosine 1-phosphate metabolism. Circ Res. 2004;94:724-734.
49. Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1- phosphate. Science. 2007;316:295-298. (Pubitemid 46633109)
50. Murata N, Sato K, Kon J, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J. 2000;352:809-815. (Pubitemid 32015038)
51. Okajma F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphae: Is this an atherogenic mediator or an antiatherogenic mediator? Biochim Biophys Acta. 2002;1582:132-137.
52. Deutschman DH, Carstens JS, Klepper RL, et al. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J. 2003;146:62-68. (Pubitemid 36851301)
53. Tani M, Sano T, Ito M, et al. Mechanisms of sphingosine and sphingosine 1-phosphate generation in human platelets. J Lipid Res. 2005;46:2458-2467. (Pubitemid 41532534)
54. Venkataraman K, Lee YM, Michaud J, et al. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res. 2008;102: 669-676.
55. Schwab SR, Pereira JP, Matloubian M, et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science. 2005;309:1735-1739. (Pubitemid 41285945)
56. Bünemann M, Brandts B, Meyer zu Heringdorf D, et al. Activation of muscarinic K+ current in guinea-pig atrial myocytes by sphingosine-1- phosphate. J Physiol. 1995;489:701-707. (Pubitemid 26016920)
57. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4:397-407.
58. Hla T, Lee MJ, Ancellin N, et al. Lysophospholipid-receptor revelations. Science. 2001;294:1875-1878.
59. Usui S, Sugimoto N, Takuwa N, et al. Blood lipid mediator sphingosine 1-phosphate potently stimulates platelet-derived growth factor-A and -B chain expression through S1P1-Gi-Ras-MAPK-dependent induction of Kruppel-like factor 5. J Biol Chem. 2004;279:12300-12311. (Pubitemid 38445796)
60. Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling in mammalian cells. Biochem J. 2000;349:385-402. (Pubitemid 30465772)
61. Landeen LK, Dederko DA, Kondo CS, et al. Mechanisms of the negative inotropic effects of sphingosine-1-phosphate on adult mouse ventricular myocytes. AM J Physiol Heart Circ Physiol. 2008;294: H736-H749.
62. Mazurais D, Robert P, Gout B, et al. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem. 2002;50:661-670. (Pubitemid 34437559)
63. Zondag GC, Postma FR, Etten IV, et al. Sphingosine 1-phosphate signalling through the G-protein-coupled receptor Edg-1. Biochem J. 1998;330:605-609.
64. Okamoto H, Takuwa N, Gonda K, et al. EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition. J Biol Chem. 1998;273:27104-27110. (Pubitemid 28500416)
65. Kon J, Sato K, Watanable T, et al. Comparison of intrinsic activities of the putative sphingosine 1-phosphate receptor subtypes to regulate several signaling pathways in their cDNA-transfected Chinese hamster ovary cells. J Biol Chem. 1999;274:23940-23947. (Pubitemid 129528435)
66. Nofer JR, van der Giet M, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004;113:569-581. (Pubitemid 38542506)
67. Lorenz JN, Arend LJ, Robitz R, et al. Vascular dysfunction in S1P2 sphingosine 1-phosphate receptor knockout mice. Am J Physiol Regul Integr Comp Physiol. 2007;292:R440-R446. (Pubitemid 46089859)
68. Xin C, Ren S, Pfeilschifter J, et al. Heterologous desensitization of the sphingosine-1-phosphate receptors by purinoceptor activation in renal mesangial cells. Br J Pharmacol. 2004;143:581-589. (Pubitemid 39524275)
69. Oo ML, Thangada S, Wu MT, et al. Immunosuppressive and antiangiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem. 2007;282:9082-9089. (Pubitemid 47093504)
70. Graler MH, Goetzl EJ. The immunosupressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. 2004; 18:551-553.
71. Jo E, Sanna MG, Gonzalez-Cabrera PJ, et al. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol. 2005;12:703-715. (Pubitemid 43142048)
72. Liu CH, Thangada S, Lee MJ, et al. Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1. Mol Biol Cell. 1999;10: 1179-1190. (Pubitemid 29193739)
73. Igarashi J, Michel T. Agonist-modulated targeting of the EDG-1 receptor to plasmalemmal caveolae. J Biol Chem. 2000;275:32363-32370.
74. Kohno T, Wasa A, Igarashi Y. N-glycans of sphingosine 1-phosphate receptor Edg-1 regulate ligand-induced receptor internalization. FASEB J. 2002;16:983-992. (Pubitemid 34753504)
75. Gonzalez-Cabrera PJ, Hla T, Rosen H. Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation and proteomics. J Biol Chem. 2007;282:7254-7264. (Pubitemid 47093659)
76. Karliner JS. Mechanisms of cardioprotection by lysophospholipids. J Cell Biochem. 2004;92:1095-1103.
77. Nakajima N, Cavalli AL, Biral D, et al. Expression and characterization of Edg-1 receptors in rat cardiomyocytes. Calcium deregulation in response to sphingosine 1-phosphate. Eur J Biochem. 2000;267:5679-5686. (Pubitemid 30706934)
78. Robert P, Tsui P, Laville MP, et al. EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J Mol Cell Cardiol. 2001; 33:1589-1606. (Pubitemid 32844218)
79. Ohmori T, Yatomi Y, Osada M, et al. Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc Res. 2003;58:170-177. (Pubitemid 36351635)
80. Sanna MG, Liao J, Jo E, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004;279:13839-13848. (Pubitemid 38468916)
81. Landeen LK, Dederko DA, Kondo CS, et al. Mechanisms of the negative inotropic effects of sphingosine-1-phosphate on adult mouse ventricular myocytes. Am J Physiol Heart Circ Physiol. 2008;294:H736-H749.
82. Tsukada YT, Sanna MG, Rosen H, et al. S1P1-selective agonist SEW2871 exacerbates reperfusion arrhythmias. J Cardiovasc Pharmacol. 2007;50:660-669. (Pubitemid 350307036)
83. Pan S, Mi Y, Pally C, et al. A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol. 2006;13:1227-1234. (Pubitemid 44762192)
84. Oyama O, Sugimoto N, Qi X, et al. The lysophospholipid mediator sphingosine-1-phosphate promotes angiogenesis in vivo in ischaemic hindlimbs of mice. Cardiovasc Res. 2008;78:301-307. (Pubitemid 351556099)
85. Pebay A, Bonder CS, Pitson SM. Stem cell regulation by lysophospholipids. Prostaglandins Other Lipid Mediat. 2007;84:83-97.
86. Donati C, Bruni P. Sphingosine 1-phosphate regulates cytoskeleton dynamics: implications in its biological response. Biochim Biophys Acta. 2006;1758:2037-2048. (Pubitemid 44879361)
87. Karliner JS, Honbo N, Summers K, et al. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol. 2001;33:1713-1717. (Pubitemid 32844228)
88. Zhang J, Honbo N, Goetzl EJ, et al. Signals from type 1 sphingosine 1- phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol. 2007;293: H3150-H3158. (Pubitemid 350106541)
89. Davis MD, Clemens JJ, Macdonald TL, et al. Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem. 2005;280:9833-9841.
90. Means CK, Miyamoto S, Chun J, et al. S1P1 receptor localization confers selectivity for Gi-mediated cAMP and contractile responses. J Biol Chem. 2008;283:11954-11963.
91. 3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2007; 292:H2944-H2951.
92. Allende ML, Yamashita T, Proia RL. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood. 2003;102:3665-3667. (Pubitemid 37409386)
93. Allende ML, Zhou D, Kalkofen DN, et al. S1P1 receptor expression regulates emergence of NKT cells in peripheral tissues. FASEB J. 2008; 22:307-315.
94. Lee Y-M, Venkatgaraman K, Hwang S-I, et al. A novel method to quantify sphingosine 1-phosphate by immobilized metal affinity chromatography (IMAC). Prostaglandins Other Lipid Mediat. 2007; 84:154-162.
95. Jin ZQ, Zhou HZ, Zhu P, et al. Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol. 2002; 282:H1970-H1977. (Pubitemid 34663002)
96. Lecour S, Smith RM,Woodward B, et al. Identification of a novel role for sphingolipid signaling in TNFa and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol. 2002;34:509-518.
97. Gray MO, Zhou HZ, Schafhalter-Zoppoth I, et al. Preservation of baseline hemodynamic function and loss of inducible cardioprotection in adult mice lacking protein kinase C epsilon. J Biol Chem. 2004;279: 3596-3604 (Pubitemid 38140600)
98. Jin Z-Q, Goetzl EJ, Karliner JS. Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation. 2004;110:1980-1989.
99. Jin Z-Q, Karliner JS. Low dose N,N-dimethylsphingosine is cardioprotective and activates cytosolic sphingosine kinase by a PKCe dependent mechanism. Cardiovasc Res. 2006;71:725-734.
100. 2+ transients and L-type Ca2+ channel conductance. Circ Res. 1994;75:981-989.
101. Suzuki E, Handa K, Toledo MS, et al. Sphingosine-dependent apoptosis: a unified concept based on multiple mechanisms operating in concert. Proc Natl Acad Sci U S A. 2004;101:14788-14793. (Pubitemid 39410753)
102. Vessey DA, Li L, Kelley M, et al. Sphingosine can pre-and postcondition heart and utilizes a different mechanism from sphingosine 1- phosphate. J Biochem Mol Toxicol. 2008;22:113-118. (Pubitemid 351657194)
103. Vessey DA, Kelley M, Karliner JS. A rapid radioassay for sphingosine kinase. Anal Biochem. 2005;337:136-142.
104. Vessey DA, Kelley M, Li L, et al. Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. Med Sci Monit. 2006;12:318-324. (Pubitemid 44556077)
105. Jin Z-Q, Zhang J, Huang Y, et al. A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc Res. 2007;76:41-50. (Pubitemid 47362044)
106. Nishino Y, Webb I, Marber MS. Sphingosine kinase isoforms and cardiac protection [editorial]. Cardiovasc Res. 2007;76:3-4. (Pubitemid 47364794)
107. Duan H-F, Wang H, Yi J, et al. Adenoviral gene transfer of sphingosine kinase 1 protects heart against ischemia/reperfusion-induced injury and attenuates its postischemic failure. Human Gene Ther. 2007;18:1119-1128. (Pubitemid 350114687)
108. Kim M, Kim M, Kim N, et al. Isoflurane mediates protection from renal ischemia-reperfusion injury via sphingosine kinase and sphingosine-1- phosphate-dependent pathways. Am J Physiol Renal Physiol. 2007;293: F1827-F1835. (Pubitemid 350179608)
109. Zhao ZQ, Corvera JS, Jalos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285: H579-H588. (Pubitemid 36885888)
110. Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation. 2008;117:1037-1044.
111. Jin Z-Q, Karliner JS, Vessey DA. Ischaemic postconditioning protects isolated mouse hearts against ischaemia/reperfusion injury via sphingosine kinase isoform-1 activation. Cardiovasc Res. 2008;79:134-140.
112. Vessey DA, Li L, Kelley M, et al. Combined sphingosine, S1P and ischemic postconditioning rescue the heart after protracted ischemia. Biochem Biophys Res Commun. 2008;375:425-429.
113. Kacimi R, Vessey DA, Honbo N, et al. Adult cardiac fibroblasts null for sphingosine kinase-1 exhibit growth dysregulation and an enhanced proinflammatory response. J Mol Cell Cardiol. 2007;43:85-91. (Pubitemid 46898421)
114. Nofer J-R, Levkau B, Wolinska I, et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem. 2001;276:34480-34485. (Pubitemid 37384437)
115. Kimura T, Sato K, Malchinkhuu E, et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1- phosphate and its receptors. Arterioscler Thromb Vasc Biol. 2003;23: 1283-1288. (Pubitemid 36871285)
116. Tolle M, Levkau B, Kleuser B, et al. Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds. Eur J Clin Invest. 2007;37:171-179. (Pubitemid 46310587)
117. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2007;115:501-508. (Pubitemid 46188244)
118. Keul P, Tolle M, Lucke S, et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:607-613. (Pubitemid 46263407)
119. Igarashi J, Miyoshi M, Hashimoto T, et al. Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to highdensity lipoproteins. Br J Pharmacol. 2007;150:470-479. (Pubitemid 46280654)
120. Keul P, Sattler K, Levkau B. HDL and its sphingosine-1-phosphate content in cardioprotection. Heart Fail Rev. 2007;12:301-306. (Pubitemid 350176703)
121. Argraves KM, Argraves WS. HDL serves a S1P signaling platform mediating a multitude of cardiovascular effects. J Lipid Res. 2007;48: 2325-2333.
122. Levkau B, Hermann S, Theilmeier G, et al. High-density lipoprotein stimulatesmyocardial perfusion in vivo. Circulation. 2004;110:3355-3359. (Pubitemid 39557499)
123. 3 lysophospholipid receptor. Circulation. 2006;114:1403-1409.
124. Karliner JS. Toward solving the riddle. The enigma becomes less mysterious. Circ Res. 2006;99:465-467.